The tweet was deleted by the author.
But we saved everything 🙂.
Lia Holmgren highlights that HIMS is currently testing a resistance level, with the next key target set at $40. There is also notable GEX activity now building at $50.
Holmgren further mentions that the Trump administration plans to ease restrictions on testosterone therapy.
Holmgren has previously advised caution on SPCX stock due to limited liquidity and low trading volume. She has also noted technical patterns in the healthcare sector, observing XLV testing resistance levels. These past comments add further context to her current analysis of HIMS price action.